Wall Street Journal - April 8



April 8 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

- Walmart Inc WMT.N is raising starting pay for in-house truck drivers to as much as $110,000 a year and expanding a program that trains its existing workers to become drivers. Link

- Tesla Inc TSLA.O Chief Executive Elon Musk delivered the company's first made-in-Texas vehicles on Thursday, saying the company was entering a new phase and teasing coming products including a dedicated robotaxi. Link

- Pfizer PFE.N said on Thursday it had reached a deal to purchase privately held ReViral Ltd and its experimental drug sisunatovir for up to $525 million if milestones are met. Link

- U.S. Medicare will deny routine payment for Biogen Inc's BIIB.O Alzheimer's disease drug Aduhelm, finalizing an unusually strict policy that will require patients to enroll in clinical trials so the government will pay for the drug. Link

(Compiled by Bengaluru newsroom)

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.